Form 4: CFO LeBlanc Acquires LeMaitre Vascular Dividend Rights

LeMaitre Vascular's CFO, Dorian LeBlanc, acquired 2.8691 dividend equivalent rights, accruing on a restricted stock unit award.

Summary

• Dorian LeBlanc, Chief Financial Officer of LeMaitre Vascular, Inc. (LMAT), acquired 2.8691 dividend equivalent rights.
• These rights accrued on a restricted stock unit (RSU) award that was granted on March 10, 2025.
• The dividend equivalent rights vest proportionately with the underlying RSU award.
• Each dividend equivalent right is economically equivalent to one share of LeMaitre Vascular's common stock.
• Following this transaction, Mr. LeBlanc beneficially owns 11.3269 derivative securities, specifically dividend equivalent rights.
• The transaction was executed on December 4, 2025, and was made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 6

Explanation: The acquisition of dividend equivalent rights is a routine, positive event for the insider, reflecting ongoing compensation and alignment with shareholder interests. It's not a major market-moving event for the company.

Positives

• The acquisition of dividend equivalent rights increases the beneficial ownership for the CFO, aligning interests with shareholders.
• The transaction was made under a Rule 10b5-1(c) plan, indicating a pre-scheduled, non-discretionary transaction.

Negatives

• No specific negatives are identified in this routine insider transaction filing.

Risks

• The reporting person (Dorian LeBlanc) acknowledges responsibility to comply with Section 16 and Regulation 13D-G of the Securities Exchange Act of 1934.
• Dorian LeBlanc agrees to indemnify the attorneys-in-fact and the Company against any demand, damage, loss, cost, or expense arising from any false or misleading information provided by LeBlanc.

Future Outlook

The filing does not contain specific forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• These dividend equivalent rights accrued on a restricted stock unit award granted on 3/10/2025 and vest proportionately with such award.
• Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

Industry Context

This is a routine insider transaction related to executive compensation, common across publicly traded companies, and does not reflect broader industry trends or competitive dynamics.

Comparison to Industry Standards

• The acquisition of dividend equivalent rights as part of a restricted stock unit award is a standard component of executive compensation packages in many industries, including the medical device sector.
• This practice aligns executive incentives with shareholder returns by linking compensation to company performance and dividend distributions.
• No specific comparable companies or projects are detailed in this filing.

Corporate Governance

Related Party Transactions

• The acquisition of dividend equivalent rights by the Chief Financial Officer from the company is a related party transaction, typical for executive compensation.

Stakeholder Impact

• Shareholders: Minor positive impact due to increased alignment of CFO's interests with shareholder returns through equity-based compensation.
• Employees: No direct impact on general employees.
• Management: Streamlined SEC reporting for the CFO through the Power of Attorney.

Next Steps

• The dividend equivalent rights will vest proportionately with the underlying restricted stock unit award.

Key Dates

Keywords

LeMaitre Vascular, LMAT, Dorian LeBlanc, CFO, Form 4, SEC filing, insider transaction, dividend equivalent rights, restricted stock units, equity compensation, corporate governance